Patricia Bononi, MD
Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1730105586
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,915 of the $91,201 with a category attached, or 69.0%. Novo Nordisk accounts for 76.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $26,348 and has fallen 52.0% since, to $12,640 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $394.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$70K
- Eli Lilly$4K
- Sanofi-aventis U.S. LLC$4K
- Ascensia Diabetes Care US Inc.$4K
- Corcept Therapeutics$4K
- Medtronic$2K
- plus $5K from 19 others
Across 20 payments — averaging $869.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
- Novo Nordisk AS$411
What the payments were for
- Consulting fees$13,50815%
- Speaking & faculty fees$62,91569%
- Travel & lodging$5,6426%
- Food & beverage$8,5419%
- Education$5961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 106 | $69,747 |
| Eli Lilly | 24 | $3,866 |
| Sanofi-aventis U.S. LLC | 4 | $3,757 |
| Ascensia Diabetes Care US Inc. | 7 | $3,724 |
| Corcept Therapeutics | 6 | $3,592 |
| Medtronic(2 entities) | 8 | $1,699 |
| Dexcom, Inc. | 22 | $1,099 |
| Amgen | 10 | $847 |
| Cequr Corporation | 4 | $752 |
| Abbott | 5 | $424 |
| Bigfoot Biomedical Inc | 2 | $396 |
| Tandem Diabetes Care, Inc. | 7 | $367 |
| W. L. Gore & Associates, Inc. | 2 | $259 |
| BETA Bionics, Inc. | 3 | $206 |
| Lilly USA, LLC | 5 | $106 |
| Sequel Med Tech, LLC | 3 | $76 |
| Insulet Corporation | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Coopersurgical, Inc. | 1 | $26 |
| Bayer | 1 | $25 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$31,120
- Ozempic$30,572
- SOLIQUA 100/33$3,604
- Korlym$3,546
- Victoza$1,870
- Minimed 670G System$1,484
- CeQur Simplicity$711
- DEXCOM G6 TRANSMITTER$479
- iLet Bionic Pancreas$444
- UNITY DIABETES MANAGEMENT SYSTEM$300
- FreeStyle Lite system$200
- SEAMGUARD$139
- t-slim insulin pump$125
- EVENITY$122
- SEAMGUARD Staple Line Reinforcement$120
- Prolia$116
- DEXCOM G7 GSS (161)$105
How this compares
$91,201 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 239 | $417,386 |
| TrulicityDulaglutide | 103 | $138,357 |
| MounjaroTirzepatide | 102 | $131,750 |
| JardianceEmpagliflozin | 105 | $122,069 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 79 | $64,697 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $48,245 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $45,015 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $40,843 |
| TymlosAbaloparatide | 11 | $28,864 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $27,190 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 175 | $25,463 |
| FarxigaDapagliflozin Propanediol | 16 | $25,052 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $23,410 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $22,179 |
| InvokanaCanagliflozin | 12 | $19,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $69,747 | $443,585276 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $106 | $281,071239 claims |
| AstraZenecaFarxiga | $16 | $25,05216 claims |
| Cequr CorporationCequr Simplicity | $752 | $14,53228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Pittsburgh
- Vijay BahlPittsburgh$998K
- Swarna VarmaPittsburgh$520K
- Sachin BahlPittsburgh$162K
- Peter GrondziowskiPittsburgh$143K
- Murray GordonPittsburgh$60K
- Frederico ToledoPittsburgh$50K
- Hugo LinPittsburgh$21K
- Pouneh FazeliPittsburgh$20K
- Serge JabbourPhiladelphia$1.2M
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.